Bifidobacterium bifidumand Diarrhea.
Evidence gradeA
ImpactStrong
Confidencehigh
Imported rating. This grade comes from SuppCo and has not been independently reviewed. It describes research, not a product, and it is not medical advice.
The rating
- Direction
- Favourable
- Rated by
- SuppCo
- Observed
- 28 September 2026
Studies behind it
The Short-Term Efficacy of Bifidobacterium Quadruple Viable Tablet in Patients With Diarrhea-Predominant Irritable Bowel Syndrome: Potentially Mediated by Metabolism Rather Than Diversity RegulationT. Bai · The American Journal of Gastroenterology2022Meta-analysis of the effects of Bifidobacterium preparations for the prevention and treatment of pediatric antibiotic-associated diarrhea in China.Hong-bin Xu · Complementary therapies in medicine2017Effect of Bifidobacterium bifidum G9-1 on the Intestinal Environment and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-like Symptoms in Patients with Quiescent Crohn’s Disease: A Prospective Pilot StudyT. Tomita · Journal of Clinical Medicine2023